A detailed history of Affinity Asset Advisors, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 400,000 shares of ACLX stock, worth $30.2 Million. This represents 5.77% of its overall portfolio holdings.

Number of Shares
400,000
Previous 460,000 13.04%
Holding current value
$30.2 Million
Previous $25.4 Million 31.58%
% of portfolio
5.77%
Previous 3.46%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$50.91 - $86.61 $3.05 Million - $5.2 Million
-60,000 Reduced 13.04%
400,000 $33.4 Million
Q2 2024

Aug 14, 2024

BUY
$49.74 - $66.98 $7.96 Million - $10.7 Million
160,000 Added 53.33%
460,000 $25.4 Million
Q1 2024

May 14, 2024

SELL
$51.85 - $73.49 $2.07 Million - $2.94 Million
-40,000 Reduced 11.76%
300,000 $20.9 Million
Q4 2023

Feb 13, 2024

SELL
$31.75 - $57.99 $1.91 Million - $3.48 Million
-60,000 Reduced 15.0%
340,000 $18.9 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $5.47 Million - $6.5 Million
173,725 Added 76.78%
400,000 $14.4 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $644,393 - $1.1 Million
23,441 Added 11.56%
226,275 $7.15 Million
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $1 Million - $1.27 Million
-37,309 Reduced 15.54%
202,834 $6.25 Million
Q4 2022

Feb 13, 2023

BUY
$17.18 - $33.0 $515,485 - $990,165
30,005 Added 14.28%
240,143 $7.44 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $2.25 Million - $2.98 Million
135,138 Added 180.18%
210,138 $3.94 Million
Q2 2022

Aug 12, 2022

BUY
$7.21 - $24.43 $540,750 - $1.83 Million
75,000 New
75,000 $1.36 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.31B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.